FAQs

The CAR-TCR Summit is the world’s definitive, industry led cell therapy conference, taking place September 23 – 26 in Boston. The agenda features:

• 100+ expert speakers from every pocket of the cell therapy ecosystem
• All stages of pipeline development from translation through to commercialization
• 7 cell types including T, NK, macrophage, gamma delta, and TILs
• Both oncological and autoimmune indications
• 4 focus days, dedicated to fundamentals, solid tumor targeting, automated manufacturing, and forging strategic partnerships

You can find your complete guide to the meeting here.

The summit is designed to benefit biopharma professionals, academic researchers, and solution providers working in cell therapy development, manufacturing, clinical trials, regulatory strategy, and more.

Attendee breakdown is available in the full event guide.

The four-day program includes:

• A pre-conference day featuring 6 workshops, the cell therapy fundamentals day, and biotech and pharma partnering day
• 5-tracked main conference agenda, spanning: discovery and translation, clinical development, early-stage manufacturing, late-stage manufacturing, analytical development
• A post-conference day featuring the solid tumors, and automation focus days

See the full agenda here.

Key sessions include:

• New in vivo CAR clinical data for B-cell diseases with Capstan Therapeutics, to understand the advantages of in vivo CAR-T and considerations for clinical scalability
• New clinical data from Legend Biotech’s CAR-T targeting Claudin 18.2 and DLL3 for gastric cancer and small cell lung cancer to help further progress in solid tumor targeting
• Investor insights from Truist Securities to understand how to harmonize relationships with investors to increase funding opportunities
• Explore best practices for analytical method lifestyle management with Bristol Myers Squibb to reduce analytical testing time and improve product characterization
• Dive into process automation to help decentralized production for autologous cell therapies with Galapagos

See full session breakdowns in the event guide.

The 10^th CAR-TCR Summit features a speaker faculty of 100+ experts, including investors and partnering leaders, founders and c-level leaders, and pharma and biotech leaders, and pioneering academics.

Here’s a snapshot of the faculty:

• Aaron Cooper, Vice President, Early Discovery, Arsenal Bio
• Mark Cobbold, Senior Vice President Immuno-Oncology, Discovery & Cell Therapy Oncology, AstraZeneca
• Peter Gergely, Global Head of Immunology, Translational Medicine, Novartis
• Alexis Melton, Director, Early Clinical Development Haematology & Cell Therapy, Bristol Myers Squibb
• Anna Truppel-Hartmann, Chief Medical Officer, KSQ Therapeutics
• Naji Gehchan, Chief Medical & Development Officer, Kyverna Therapeutics
• Christopher Tan, Executive Director, Search & Evaluation Business Development & Licensing, Merck
• Kingyin Lee, Head of Clinical Trials, MHRA
• Nan Zhang, Chief, Cell Therapy Manufacturing Section, NIH
• Tom Kowski, Vice President, Analytical Development, Umoja Biopharma

See the full speaker line-up here.

Are there any discounts available?

Group discounts are available, with up to 20% off when registering 5 or more attendees from the same company.

Full T&Cs are available here.

For inquiries regarding registration, speaking, or press, contact info@hansonwade.com. For sponsorship inquiries, please contact sponsor@hansonwade.com